Cited by 222Immunotherapy and Immune ResponsesVirus-based gene therapy researchBacterial Cancer Therapy

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

Viral Vector-Based Therapeutic Cancer Vaccines

Open access

Larocca, Cecilia, Schlom, Jeffrey·2011·The Cancer Journal

DOI 10.1097/ppo.0b013e3182325e63PMC PMC3207353

Open this paper in CoChat — free account

Abstract

Most viruses are naturally immunogenic and can be engineered to express tumor antigen transgenes. Moreover, many types of recombinant viruses have been shown to infect professional antigen-presenting cells, specifically dendritic cells, and express their transgenes. This enhanced presentation of tumor antigens to the immune system has led to an increase in the frequency and avidity of cytotoxic T lymphocytes that target tumor cells expressing the tumor antigen(s) encoded in the vaccine vector. Logistically, recombinant viruses can be produced, administered, and quality controlled more easily compared with other immunotherapy strategies. The intrinsic properties of each virus have distinct advantages and disadvantages, which can determine their applicability in a particular therapeutic setting. The disadvantage of some vectors is the development of host-induced neutralizing antibodies to the vector itself, thus limiting its continued use. The "off-the-shelf" nature of viral vaccine platforms renders them exceptionally suitable for multicenter randomized trials. This review described and discussed the strategies used and results using viral-based vaccines, with emphasis on phases II and III clinical trials. Future directions will involve the evaluation of viral-based vaccines in the adjuvant and neoadjuvant settings, in patients with low burden metastatic disease, and in combination with other forms of therapy including immunotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/ppo.0b013e3182325e63

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases
Choti, M. A., Sitzmann, J. V., Tiburi, M. F., Sumetchotimetha, W., Rangsin, R., Schulick, R. D., Lillemoe, K. D., Yeo, C. J., & Cameron, J. L. (2002) · Annals of Surgery · doi:10.1097/00000658-200206000-00002 · Cited by 1,456
Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases
Pawlik, T. M., Scoggins, C. R., Zorzi, D., Abdalla, E. K., Andrès, A., Eng, C., Curley, S. A., Loyer, E. M., Muratore, A., Mentha, G., et al. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000160703.75808.7d · Cited by 1,103
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glodé, L. M., Bilhartz, D. L., Wyand, M. S., Manson, K. H., Panicali, D., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 994
Self-citation
Survival after Hepatic Resection for Metastatic Colorectal Cancer: Trends in Outcomes for 1,600 Patients during Two Decades at a Single Institution
House, M. G., Ito, H., Gönen, M., Fong, Y., Allen, P. J., DeMatteo, R. P., Brennan, M. F., Blumgart, L. H., Jarnagin, W. R., & D'Angelica, M. I. (2010) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2009.12.040 · Cited by 517
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
Moss, B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11341 · Cited by 515
Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine
Tsang, K.-Y., Zaremba, S., Nieroda, C. A., Zhu, M., Hamilton, J. M., & Schlom, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.13.982 · Cited by 498
Self-citation
Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer
Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
Gulley, J. L., Arlen, P. M., Bastian, A., Morin, S., Marté, J. L., Beetham, P. K., Tsang, K.-Y., Yokokawa, J., Hodge, J. W., Ménard, C. M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2062 · Cited by 370
Self-citation
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
Pelzer, U., Schwaner, I., Stieler, J., Adler, M., Seraphin, J., Dörken, B., Riess, H. B., & Oettle, H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.011 · Cited by 369
Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses
Marshall, J. L., Hoyer, R. J., Toomey, M. A., Faraguna, K., Chang, P., Richmond, E. S., Pedicano, J. E., Gehan, E. A., Peck, R. A., Arlen, P. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3964 · Cited by 356
Self-citation

Show all 85 references

Sorted by citations

Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer
Picard, E., Verschoor, C. P., Grace, W. K., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00369 · Cited by 533
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 454
Oncolytic virus immunotherapy: future prospects for oncology
Raja, J. Y., Ludwig, J. M., Gettinger, S. N., Schalper, K. A., & Kim, H. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0458-z · Cited by 321
Gene Therapies for Cancer: Strategies, Challenges and Successes
Das, S. K., Menezes, M. E., Bhatia, S., Wang, X., Emdad, L., Sarkar, D., & Fisher, P. B. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24791 · Cited by 298
The dawn of vaccines for cancer prevention
Finn, O. J. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.140 · Cited by 257
Human Tumor Antigens and Cancer Immunotherapy
Vigneron, N. (2015) · BioMed Research International · doi:10.1155/2015/948501 · Cited by 254
Best practices for bioinformatic characterization of neoantigens for clinical utility
Richters, M. M., Xia, H., Campbell, K. M., Gillanders, W. E., Griffith, O. L., & Griffith, M. (2019) · Genome Medicine · doi:10.1186/s13073-019-0666-2 · Cited by 217
Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities
Antonioli, L., Yegutkin, G. G., Pacher, P., Blandizzi, C., & Haskó, G. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.01.003 · Cited by 218
Cancer Vaccines, Adjuvants, and Delivery Systems
Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200
Impact of the immune system and immunotherapy in colorectal cancer.
Markman, J. L., & Shiao, S. L. (2015) · PubMed Central · doi:10.3978/j.issn.2078-6891.2014.077 · Cited by 201
mRNA vaccines for cancer immunotherapy
Vishweshwaraiah, Y. L., & Dokholyan, N. V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1029069 · Cited by 184
Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy
Wood, L. M., & Paterson, Y. Y. W. (2014) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2014.00051 · Cited by 163
A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer
Morse, M. A., Niedzwiecki, D., Marshall, J. L., Garrett, C. H., Chang, D. Z., Aklilu, M., Crocenzi, T. S., Cole, D. J., Dessureault, S., Hobeika, A. C., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318292919e · Cited by 142
New viral vectors for infectious diseases and cancer
Sasso, E., D’Alise, A. M., Zambrano, N., Scarselli, E., Folgori, A., & Nicosia, A. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101430 · Cited by 120
Engineered materials for cancer immunotherapy
Cheung, A. S., & Mooney, D. J. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.007 · Cited by 108
Trial Watch
Pol, J. G., Bloy, N., Obrist, F., Eggermont, A. M. M., Galon, J., Fridman, W. H., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28185 · Cited by 107
Therapeutic Cancer Vaccines
Schlom, J., Hodge, J. W., Palena, C., Tsang, K.-Y., Jochéms, C., Greiner, J. W., Farsaci, B., Madan, R. A., Heery, C. R., & Gulley, J. L. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00002-0 · Cited by 103
Self-citation
Advances in gene-based vaccine platforms to address the COVID-19 pandemic
Pushparajah, D., Jimenez, S., Wong, S. L., Alattas, H., Nafissi, N., & Slavcev, R. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.003 · Cited by 99
Immunotherapy for colorectal cancer
Koido, S. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i46.8531 · Cited by 88
Therapeutic cancer vaccine: building the future from lessons of the past
Tran, T., Blanc, C., Granier, C., Saldmann, A., Tanchot, C., & Tartour, É. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0691-z · Cited by 85
Therapeutic vaccines for breast cancer: Has the time finally come?
Corti, C., Giachetti, P. P. M. B., Eggermont, A. M. M., Delaloge, S., & Curigliano, G. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.027 · Cited by 84
Advances in immunotherapy for the treatment of glioblastoma
Tivnan, A., Heilinger, T., Lavelle, E. C., & Prehn, J. H. M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2299-2 · Cited by 83
Trial watch
Senovilla, L., Vacchelli, E., Garcia, P., Eggermont, A. M. M., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23803 · Cited by 85
Immunotherapeutic approaches to ovarian cancer treatment
Chester, C., Dorigo, O., Berek, J. S., & Kohrt, H. E. K. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0051-7 · Cited by 84
Immunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress
Rastin, F., Javid, H., Oryani, M. A., Rezagholinejad, N., Afshari, A. R., & Karimi‐Shahri, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111055 · Cited by 86
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
Nanovaccines: An effective therapeutic approach for cancer therapy
Gurunathan, S., Pratheep, T., Wang, L., Cao, Q., & Kim, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115992 · Cited by 78
Clinical applications of attenuated MVA poxvirus strain
Gómez, C. E., Perdiguero, B., García‐Arriaza, J., & Estéban, M. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.845531 · Cited by 73
Cancer Vaccines: Promising Therapeutics or an Unattainable Dream
Donninger, H., Li, C., Eaton, J. W., & Yaddanapudi, K. (2021) · Vaccines · doi:10.3390/vaccines9060668 · Cited by 74
Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches
Davodabadi, F., Sarhadi, M., Arabpour, J., Sargazi, S., Rahdar, A., & Diez-Pascual, A. M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.036 · Cited by 75
Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines
Oladejo, M., Paulishak, W., & Wood, L. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.003 · Cited by 75
The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma
Ernst, M. K., & Giubellino, A. (2022) · Biomedicines · doi:10.3390/biomedicines10040822 · Cited by 78
Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer
Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. (2023) · Pharmaceuticals · doi:10.3390/ph16101384 · Cited by 84
Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment
Dewitte, H., Verbeke, R., Breckpot, K., Smedt, S. C. D., & Lentacker, I. (2014) · Nano Today · doi:10.1016/j.nantod.2014.10.001 · Cited by 71
Microneedles: an innovative platform for gene delivery
McCaffrey, J., Donnelly, R. F., & McCarthy, H. O. (2015) · Drug Delivery and Translational Research · doi:10.1007/s13346-015-0243-1 · Cited by 68
The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines
Mok, D. Z. L., & Chan, K. R. (2020) · Viruses · doi:10.3390/v12050520 · Cited by 68
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortés, J., Romero, P. J., Mittendorf, E., Disis, M. L., & Curigliano, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2153 · Cited by 64
Colorectal cancer vaccines: The current scenario and future prospects
Jia, W., Zhang, T., Huang, H., Feng, H., Wang, S., Guo, Z., Luo, Z., Ji, X., Cheng, X., & Zhao, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.942235 · Cited by 62
Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery
Falcone, N., Ermis, M., Tamay, D. G., Mecwan, M. M., Monirizad, M., Mathes, T. G., Jucaud, V., Choroomi, A., de Barros, N. R., Zhu, Y., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301096 · Cited by 60
Fighting breast cancer stem cells through the immune-targeting of the xCT cystine–glutamate antiporter
Ruiu, R., Rolih, V., Bolli, E., Barutello, G., Riccardo, F., Quaglino, E., Merighi, I. F., Pericle, F., Donofrío, G., Cavallo, F., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2185-1 · Cited by 52
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
Agostinetto, E., Montemurro, F., Puglisi, F., Criscitiello, C., Bianchini, G., Mastro, L. D., Introna, M., Tondini, C. A., Santoro, A., & Zambelli, A. (2022) · Cancers · doi:10.3390/cancers14092136 · Cited by 52
Exosome-based immunotherapy as an innovative therapeutic approach in melanoma
Babaei, S., Fadaee, M., Abbasi-kenarsari, H., Shanehbandi, D., & Kazemi, T. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01906-1 · Cited by 48
Photochemical Internalization: Light Paves Way for New Cancer Chemotherapies and Vaccines
Šošić, L., Selbo, P. K., Kotkowska, Z. K., Kündig, T. M., Høgset, A., & Johansen, P. (2020) · Cancers · doi:10.3390/cancers12010165 · Cited by 46
Immunotherapy in ovarian cancer
Krishnan, V., Berek, J. S., & Dorigo, O. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.11.003 · Cited by 48
Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine
Belnoue, E., Mayol, J.-F., Carboni, S., Berardino-Besson, W. D., Dupuychaffray, E., Nelde, A., Stevanović, S., Santiago‐Raber, M., Walker, P. R., & Derouazi, M. (2019) · JCI Insight · doi:10.1172/jci.insight.127305 · Cited by 46
Anti-Colorectal Cancer Effects of Probiotic-Derived p8 Protein
An, B. C., Hong, S., Park, H. J., Kim, B.-K., Ahn, J. Y., Ryu, Y., An, J. H., & Chung, M. J. (2019) · Genes · doi:10.3390/genes10080624 · Cited by 44
Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8+ T-cell recall responses
Zhang, L., Bridle, B. W., Chen, L., Pol, J. G., Spaner, D., Boudreau, J. E., Rosen, A., Bassett, J. D., Lichty, B. D., Bramson, J. L., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438481 · Cited by 43
Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses
Murthy, V., Minehart, J. C., & Sterman, D. H. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx097 · Cited by 44
Emergence in protein derived nanomedicine as anticancer therapeutics: More than a tour de force
Wang, Z., Zhi, K., Ding, Z., Sun, Y., Li, S., Li, M., Pu, K., & Zou, J. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.012 · Cited by 42
Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer
Conti, L., Bolli, E., Lorenzo, A. D., Franceschi, V., Macchi, F., Riccardo, F., Ruiu, R., Russo, L., Quaglino, E., Donofrío, G., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0082 · Cited by 42
Cowpea Mosaic Virus Outperforms Other Members of the Secoviridae as In Situ Vaccine for Cancer Immunotherapy
Beiss, V., Mao, C., Fiering, S., & Steinmetz, N. F. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00058 · Cited by 40
Bacterial and viral vectors as vaccine delivery vehicles for breast cancer therapy
Shanmugaraj, B., Priya, L. B., Mahalakshmi, B., Subbiah, S., Hu, R., Velmurugan, B. K., & Baskaran, R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117550 · Cited by 39
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37
Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis
Dafni, U., Lluesma, S. M., Balint, K., Tsourti, Z., Vervita, K., Chenal, J., Coukos, G., Zaman, K., Sarivalasis, A., & Kandalaft, L. E. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.10.014 · Cited by 41
Recent progress in cancer vaccines and nanovaccines
Poudel, K., Vithiananthan, T., Kim, J. O., & Tsao, H. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122856 · Cited by 40
Boosting CAR-T cell therapy through vaccine synergy
Li, Y.-R., Lyu, Z., Shen, X., Fang, Y., & Yang, L. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.12.004 · Cited by 40
Recombinant Viruses for Cancer Therapy
Chulpanova, D. S., Solovyeva, V. V., Kitaeva, K. V., Dunham, S. P., Khaiboullina, S. F., & Rizvanov, A. A. (2018) · Biomedicines · doi:10.3390/biomedicines6040094 · Cited by 37
Photosensitisation facilitates cross-priming of adjuvant-free protein vaccines and stimulation of tumour-suppressing CD8 T cells
Håkerud, M., Selbo, P. K., Waeckerle‐Men, Y., Contassot, E., Dziunycz, P., Kündig, T. M., Høgset, A., & Johansen, P. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.032 · Cited by 36
Breast cancer vaccination comes to age: impacts of bioinformatics
Parvizpour, S., Razmara, J., & Omidi, Y. (2018) · Bioimpacts · doi:10.15171/bi.2018.25 · Cited by 36
Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy
Bou-Dargham, M. J., Draughon, S. A., Cantrell, V., Khamis, Z. I., & Sang, Q. A. (2021) · Journal of Cancer · doi:10.7150/jca.64205 · Cited by 37
Trial watch: Naked and vectored DNA-based anticancer vaccines
Bloy, N., Buqué, A., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Sautès‐Fridman, C., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1026531 · Cited by 38
Replicating poxviruses for human cancer therapy
Kim, M. (2015) · The Journal of Microbiology · doi:10.1007/s12275-015-5041-4 · Cited by 35
Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies
Olsen, H. E., Lynn, G. M., Valdes, P. A., Cerecedo-Lopez, C. D., Ishizuka, A. S., Arnaout, O. M., Bi, W. L., Peruzzi, P. P., Chiocca, E. A., Friedman, G. K., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab027 · Cited by 35
Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity
Kim, S., Park, A. K., Chaurasiya, S., Kang, S., Lü, J., Yang, A., Sivanandam, V., Zhang, Z., Woo, Y., Priceman, S. J., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0405 · Cited by 33
Targeting Glioblastoma: The Current State of Different Therapeutic Approaches
Khan, I., Mahfooz, S., Elbasan, E. B., Karaçam, B., Öztanır, M. N., & Hatiboğlu, M. A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210113152108 · Cited by 34
Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions
Berry, J., Vreeland, T. J., Trappey, A. F., Hale, D. F., Peace, K. M., Tyler, J. A., Walker, A. S., Brown, R. A., Herbert, G. S., Yi, F., et al. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1226132 · Cited by 34
Engaging Natural Killer T Cells as ‘Universal Helpers’ for Vaccination
Speir, M., Hermans, I. F., & Weinkove, R. (2016) · Drugs · doi:10.1007/s40265-016-0675-z · Cited by 33
Viral gene delivery vectors: the next generation medicines for immune-related diseases
De Haan, P., Van Diemen, F. R., & Toscano, M. G. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1757989 · Cited by 34
Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges
Palma, M. (2025) · Vaccines · doi:10.3390/vaccines13040344 · Cited by 37
Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics
Le, I., Dhandayuthapani, S., Chacon, J. A., Eiring, A. M., & Gadad, S. S. (2022) · Vaccines · doi:10.3390/vaccines10050816 · Cited by 32
Biological delivery approaches for gene therapy: Strategies to potentiate efficacy and enhance specificity
Mohit, E., & Rafati, S. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.06.005 · Cited by 31
Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack
Bonilla, W. V., Kirchhammer, N., Marx, A., Kallert, S. M., Krzyzaniak, M. A., Lu, M., Darbre, S., Schmidt, S., Raguz, J., Berka, U., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100209 · Cited by 30
The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road
Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02052 · Cited by 27
Chemokine-Based Immunotherapy: Delivery Systems and Combination Therapies
Mohit, E., & Rafati, S. (2012) · Immunotherapy · doi:10.2217/imt.12.72 · Cited by 30
Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity
Erkes, D. A., Xu, G., Daskalakis, C., Zurbach, K. A., Wilski, N. A., Moghbeli, T., Hill, A. B., & Snyder, C. M. (2016) · Molecular Therapy · doi:10.1038/mt.2016.121 · Cited by 30
Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines
Altenburg, A. F., Trierum, S. E. V.-V., de Bruin, E., de Meulder, D., van de Sandt, C. E., van der Klis, F. R. M., Fouchier, R. A. M., Koopmans, M., Rimmelzwaan, G. F., & de Vries, R. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-24820-2 · Cited by 31
Viroimmunotherapy for Colorectal Cancer: Clinical Studies
Chaurasiya, S., & Warner, S. G. (2017) · Biomedicines · doi:10.3390/biomedicines5010011 · Cited by 28
Targeted suicide gene therapy for liver cancer based on ribozyme-mediated RNA replacement through post-transcriptional regulation
Han, S. R., Lee, C. H., Im, J. Y., Kim, J. H., Kim, J. H., Kim, S. J., Cho, Y. W., Kim, E., Kim, Y., Ryu, J.-H., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.10.036 · Cited by 28
mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy
Shariati, A., Khani, P., Nasri, F., Afkhami, H., Khezrpour, A., Kamrani, S., Shariati, F. S., Alavimanesh, S., & Modarressi, M. H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00692-9 · Cited by 27
A new era of cancer immunotherapy: vaccines and miRNAs
Sareen, G., Mohan, M., Mannan, A., Dua, K., & Singh, T. G. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04011-5 · Cited by 26
Immunotherapy in prostate cancer: review of the current evidence
Fernández‐García, E. M., Vera-Badillo, F., Pérez‐Valderrama, B., Matos-Pita, A. S., & Durán, I. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1259-6 · Cited by 28
Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines
Roesler, A. S., & Anderson, K. S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1884-4_35 · Cited by 26
Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer
Harao, M., Mittendorf, E. A., & Radvanyi, L. G. (2014) · BioDrugs · doi:10.1007/s40259-014-0114-1 · Cited by 25
Personal Neoantigen Vaccines for the Treatment of Cancer
Shetty, K. S., & Ott, P. A. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060820-111701 · Cited by 27
The role of viruses in cancer development versus cancer therapy: An oncological perspective
Javid, H., Mashhad, A. S., Yazdani, S., Oryani, M. A., Akbari, S., Rezagholinejad, N., Tajaldini, M., & Karimi‐Shahri, M. (2023) · Cancer Medicine · doi:10.1002/cam4.5694 · Cited by 25
TroVax in colorectal cancer
Rowe, J. H., & Cen, P. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.973323 · Cited by 25
Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines
Huang, C., Ramakrishnan, R., Trkulja, M., Ren, X., & Gabrilovich, D. I. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1198-9 · Cited by 25
Immunotherapy of microsatellite stable colorectal cancer: resistance mechanisms and treatment strategies
Han, Y.-J., Shao, C.-Y., Yao, Y., Zhang, Z., Fang, M., Gong, T., Zhang, Y., & Li, M. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad136 · Cited by 26
Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer
Allahverdiyev, A., Tari, G., Bağırova, M., & Abamor, E. Ş. (2018) · Journal of Breast Cancer · doi:10.4048/jbc.2018.21.e47 · Cited by 25
Protein-driven nanomedicines in oncotherapy
Casanova, I., Unzueta, U., Arroyo‐Solera, I., Céspedes, M. V., Villaverde, A., Mangues, R., & Vázquez, E. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.12.004 · Cited by 24
Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment
Dhas, N. L., Kudarha, R. R., Kulkarni, S., Soman, S., Navti, P. D., Kulkarni, J., Roy, A. A., Colaco, V., Raychaudhuri, R., Gupta, A., et al. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2910349 · Cited by 23
Semliki Forest virus biodistribution in tumor-free and 4T1 mammary tumor-bearing mice: a comparison of transgene delivery by recombinant virus particles and naked RNA replicon
Vasiļevska, J., Skrastiņa, D., Spunde, K., Garoff, H., Kozlovska, T., & Zajakina, A. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.37 · Cited by 23
Overcoming Suppressive Tumor Microenvironment by Vaccines in Solid Tumor
Xie, Y., Liu, W.-Q., Li, D., Hou, J.-C., Coghi, P. S., & Fan, X. (2023) · Vaccines · doi:10.3390/vaccines11020394 · Cited by 22
Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy
Wolfson, B., Franks, S. E., & Hodge, J. W. (2021) · Vaccines · doi:10.3390/vaccines9050509 · Cited by 22
Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy
Shebbo, S., Binothman, N., Darwaish, M., Niaz, H. A., Abdulal, R. H., Borjac, J., Hashem, A. M., & Mahmoud, A. B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1350208 · Cited by 20
Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy
Wan, Y., Simovic, B., & Walsh, S. R. (2015) · Oncolytic Virotherapy · doi:10.2147/ov.s66079 · Cited by 20

Authors: Larocca, C., & Schlom, J.
Affiliations: National Institutes of Health (US)
National Cancer Institute (US)
Corresponding author: Larocca, Cecilia
ORCID: Larocca, Cecilia
Schlom, Jeffrey
Venue: The Cancer Journal
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2011-09
Volume: 17
Issue: 5
Pages: 359-371
ISSN: 1528-9117 (ISSN-L)
DOI: 10.1097/ppo.0b013e3182325e63
PMC: PMC3207353
OpenAlex: W2076096828
Cited by: 222
References: 85
Citations by year: 2026: 7 · 2025: 20 · 2024: 25 · 2023: 21 · 2022: 16 · 2021: 20 · 2020: 16 · 2019: 10 · 2018: 14 · 2017: 9 · 2016: 9 · 2015: 17 · 2014: 17 · 2013: 15 · 2012: 5
FWCI: 1.06
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: The Cancer Journal (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Howard Hughes Medical Institute
National Institutes of Health
National Cancer Institute (ZIABC010425)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords: viral vector vaccines, therapeutic cancer vaccines, dendritic cells, antigen presentation, cytotoxic T lymphocytes, neutralizing antibodies, recombinant virus, neoadjuvant and adjuvant therapy, metastatic cancer, combination immunotherapy, clinical trials
MeSH terms: Antigens, Neoplasm, Clinical Trials as Topic, Genetic Vectors, Humans, Male, Prostatic Neoplasms, Viral Vaccines, Viruses, Vaccines, DNA, Cancer Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Viral Vector-Based Therapeutic Cancer Vaccines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks